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METHOD FOR OBTAINING CINATRINS C3 
AND C1 
FIELD OF THE INVENTION 
[0001] The present invention relates to processes for the 
synthesis of cinatrins Cl and C3 and to intermediates of said 
synthesis. It also relates to the use of said intermediates in the 
synthesis of cinatrins C 1 and C3. 
BACKGROUND OF THE INVENTION 
[0002] Cinatrins C3 ((3S,4S,5R)-3,4-dihydroxy-3-dode 
cyl-4,5-dicarboxytetrahydro-2-furanone) and C 1 ((3S,4S, 
5R)-3,4-dihydroxy-5-dodecyl-4,5-dicarboxytetrahydro-2 
furanone) belong to the family of Cinatrins. 
Cinatrin C 1 
[0003] They Were isolated in the year 1992 from the fungus 
CircinoZrichumfalcalisporum PiroZynsky (RF-641), isolated 
from living leaves of the India rubber tree (Ficus elaslica). 
The structural elucidation of Cinatrins C3 and C1 Was carried 
out by Dr. ItaZaki’s group in 1992 [ItaZaki, H.; Nagashima, 
K.; KaWamura, Y.; Matsumoto, K.; Nakai, H.; Terui, Y. J. 
Anlibiol. 1992, 45, 38-49.]. They also synthesiZed the dim 
ethyl esters of cinatrins Cl and C3 from the natural com 
pounds extracted from the fungus. HoWever, the assignment 
of the absolute con?guration performed by these authors is 
incorrect, and in the case of the dimethylated derivative of 
cinatrin C3 the folloWing con?guration Was proposed: 
Con?guration Proposed by Dr. ItaZaki 
[0004] Said con?guration Was revieWed and corrected by 
Prof. Evans’s group in 1997 [Evans, D. A.; Trotter, B. W.; 
BarroW, J. C. Tetrahedron 1997, 53, 8779-8794.], demon 
strating that it corresponds to the enantiomer con?guration 
proposed by Dr. ItaZaki shoWn above. 
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[0005] Cinatrins Cl and C3 inhibit the action of the Phos 
pholipaseAZ (PLA2) enZyme and therefore have anti-in?am 
matory activity (Farooqui, A. A.; Litski, M. L.; Farooqui, T.; 
Horrocks, L. Brain Res. Bull. 1999, 49, 139-153; Pinon, P.; 
Kaski, J. C. Rev. Esp. Cardiol. 2006, 59, 247-258). 
[0006] TWo enantioselective syntheses of Cinatrins C3 and 
C 1 have been described in the literature to date. Evans, D. A.; 
Trotter, B. W.; BarroW, J. C. Tetrahedron 1997, 53, 8779-8794 
describes the ?rst synthesis of these compounds. The key step 
in said synthesis consists of the stereoselective titanium-me 
diated aldol reaction of a tartrate-derived silylketene acetal, 
generated from (R,R)-tartaric acid di-tert-butyl ester, and an 
achiral ot-keto ester, prepared from myri stic acid benZyl ester. 
This synthesis is convergent, it comprises 5 steps and pro 
vides an overall yield of 24% for Cinatrin C3 and 31% for 
Cinatrin Cl. HoWever, the materials used are expensive and 
use various types of protecting groups. 
[0007] CuZZupe, A. N.; Di Florio, R.; White, J. M.; RiZZa 
casa, M.A. Org. Biomol. Chem. 2003, 1, 3572-3577 describes 
the second synthesis described to date for Cinatrins C3 and 
C l. The key step comprises the chelation-controlled addition 
of an organometallic reagent to an ot-hydroxyketone in the 
presence of an ester, Whereby the C4 quaternary stereogenic 
center of Cinatrin C3 is generated. From the hydrolysis of the 
dimethyl ester of Cinatrin C 1 With sodium hydroxide, a mix 
ture of Cinatrins C3 and C1 in a 1:1 ratio is obtained. The 
synthesis is linear, it comprises 18 steps and has an overall 
yield of 0.95%. 
[0008] EP 0 405 864A2, US. Pat. No. 5,120,647 and US. 
Pat. No. 5,099,034 also describe obtaining cinatrins by means 
of isolation from the culture of Circinolricumfalcalisporum 
RF-641, the subsequent hydrolysis thereof With sodium 
hydroxide to form the seco acid and esteri?cation of the 
cinatrins to form their dimethyl esters by means of reaction 
With diaZomethane. 
[0009] It is therefore necessary to provide an improved 
synthesis of cinatrins Cl and C3 in terms of ef?ciency, yield 
and cost. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0010] FIG. 1 shoWs a retrosynthetic scheme of the 
sequence leading to the compounds of formula (Ia) and (lb). 
SUMMARY OF THE INVENTION 
[0011] It has noW been found that by folloWing the syn 
thetic sequence of the invention it is possible to obtain com 
pounds of formula (Ia) and (lb), including cinatrins Cl and 
C3, in a reduced number of steps and With a high yield. Said 
process has been made possible by means of using the neW 
compounds of formula (II), (III), (V), (VI), (VII), Q(), @(I) 
and (XIII). 
[0012] Therefore, a ?rst aspect of the present invention 
relates to a process for the synthesis of a compound of for 
mula (II), an intermediate in the synthesis of the compounds 
of formula (Ia) and (lb), including cinatrins Cl and C3, their 
stereoisomers, or mixtures thereof, from a compound of for 
mula (III). 
[0013] An additional aspect relates to the compounds of 
formula (III), an intermediate of the synthesis of the com 
pounds of formula (Ia) and (lb), their stereoisomers, or mix 
tures thereof, and to processes for obtaining them. 
[0014] Other aspects of the present invention relate to com 
pounds of formula (V), (VI), (VII), Q(), @(I) and @(III), 
intermediates in the synthesis of the compounds of formula 
(Ia) and (lb), their stereoisomers, or mixtures thereof. 
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[0015] Another additional aspect relates to a process for 
obtaining the compounds of formula (Ia) and (lb), their ste 
reoisomers, or mixtures thereof, from a compound of formula 
(III). 
[0016] Another additional aspect relates to a process for 
obtaining a compound of formula (Ia), its stereoisomers, or 
mixtures thereof, from a compound of formula (III). 
[0017] Another additional aspect is aimed at a compound of 
formula (II) and to its use in the synthesis of the compounds 
of formula (Ia) or (Ib), their stereoisomers, or mixtures 
thereof. 
[0018] An additional aspect relates to the use of at least one 
compound of formula (III), (V), (VI), (VII), (X), @(I) and 
(XIII) for the synthesis of cinatrins Cl and C3, their stereoi 
somers, especially enantiomers, or mixtures thereof, as Well 
as mixtures of cinatrins C l and C3 or mixtures of their stere 
oisomers, especially enantiomers. 
DETAILED DESCRIPTION OF THE INVENTION 
Synthesis of Cinatrins Cl and C3 
[0019] According to a ?rst aspect, the present invention is 
aimed at a process for obtaining a compound of formula (II), 
an immediate precursor of cinatrins C 1 and C3, 
(11) 
O 
OH 
O 
CO2R3 
R5020 OH 
Wherein 
[0020] R2 is a Clo-Cl5 alkyl group; and 
[0021] R3 and R5 are independently selected from a substi 
tuted or unsubstituted C l-C2O alkyl group; 
its stereoisomers, or mixtures thereof; 
Which process Comprises dihydroxylating the double bond of 
a compound of formula (III) 
(111) 
OR5 
(the numbers next to each carbon indicate the numbering of 
the carbon atoms) Wherein 
[0022] R2, R3 and R5 are as de?ned above; and 
[0023] R1 is selected from a substituted or unsubstituted 
C l-C2O alkyl group. 
[0024] Therefore, the process of the invention for obtaining 
the compounds of formula (II) ?rst comprises a dihydroxy 
lation of the carbon-carbon double bond of the compound of 
formula (III), folloWed by an intramolecular cycliZation giv 
ing rise to the compound of formula (II). The stereochemistry 
of the dihydroxylation is directed by the hydroxyl in C3 of the 
compound of formula (III), therefore, depending on the ste 
reochemistry in this carbon ((R) or (8)), different stereoiso 
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mers of the compounds of formula (Ia) and (lb) can then be 
obtained. In other Words, the stereoselective dihydroxylation 
and the subsequent cycliZation are achieved in a single step. 
In any case, it is possible to invert the con?guration of said 
hydroxyl by means of a Mitsunobu type reaction (for the 
speci?c case of inverting con?guration of tertiary alcohols 
see Shi, Y.-J.; Hughes, D. L.; McNamara, J. M. Tetrahedron 
Le”. 2003, 44, 3609-3611; or Mukaiyama, T.; Shintou, T.; 
Fukumto, K. J. Am. Chem. Soc. 2003, 125, 10538-10539). 
Alternatively, if the compound of formula (III) is in racemic 
form, it Will be possible to obtain the compounds of formula 
(Ia) and (lb) in racemic form, being able to be used as such or 
separated into each of their enantiomers according to the 
methods Which are common general knowledge. 
[0025] According to a preferred embodiment, the com 
pound of formula (III) is a compound of formula (IIIa), or its 
enantiomers 
(IIIa) 
[0026] Wherein R1, R2, R3 and R5 are as de?ned above; 
and the compound of formula (II) obtained is a compound of 
formula (IIa), or its enantiomers 
(IIa) 
--IIIIICOZR3 
R5020 OH 
[0027] Wherein R2, R3 and R5 are as de?ned above. 
[0028] The dihydroxylation reaction can be performed 
under conditions knoWn by the skilled person, as described in 
Smith, M. B.; March, I. March ’s Advanced Organic Chemis 
try; John Wiley & Sons: NeW York, 2001. pp.: 1048-1051. 
According to a preferred embodiment, the dihydroxylation is 
performed in the presence of osmium tetroxide/N-methyl 
morpholine-N-oxide or potassium permanganate. 
[0029] As observed in FIG. 1, the preparation of the com 
pound of formula (III) can be carried out by means of tWo 
alternative routes. Thus, according to a preferred embodi 
ment, the compound of formula (III) is prepared by 
(a) reacting a compound of formula (V) 
(V) 
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wherein 
[0030] R1, R2 and R3 are as de?ned above; 
in the presence of a compound of formula C(11) 
(x11) 
0 
PPh3 RSOJQ 
Wherein 
[0031] 
or 
(b) oxidizing With a peroxide or With sodium periodate a 
compound of formula (V l) 
R5 is as de?ned above; 
(VI) 
R30 0 
O 
RGSe 0R5 
R10 
R2 
0 
Wherein 
[0032] R1, R2, R3 and R5 are as de?ned above; and 
[0033] R6 is selected from the group formed by C l-C3 alkyl 
and phenyl. 
[0034] According to option a) the compound of formula 
(Xll), a stabiliZed ylide, reacts With the compound of formula 
(V) to yield the compound of formula (III). Said stabiliZed 
ylide can be prepared according to knoWn methods (V Illa, M. 
J.; Warren, S]. Chem. Soc. R T1 1994, 12, 1569-1572) or be 
commercially purchased. According to a preferred embodi 
ment, said ylide is [(methoxycarbonyl)methylene]triphenyl 
phosphorane. Following option b), the hydroxyl is introduced 
in C3 of the compound of formula (111) according to condi 
tions knoWn in the state of the art, for example With a perox 
ide, preferably hydrogen peroxide, or With sodium perman 
ganate. Said introduction involves the sequence: (i) oxidation 
of the selenium atom, (ii) stereospeci?c 1,3-sigmatropic rear 
rangement, and (iii) release of the hydroxyl. For example, see 
Nishiyama, H.; Narimatsu, S.; ltoh, K. Tetrahedron Le”. 
1981, 22, 5289-5292; or Werkhoven, T. M.; Nisper, R.; 
Lugtenburg, J. J. Eur. J. Org. Chem. 1999, 11, 2909-2914. 
[0035] According to a preferred embodiment, and folloW 
ing synthetic route b), the compound of formula (V l) is pre 
pared by reacting a compound of formula @111) 
(X111) 
0 
0 
R30 
R10 R2 
SeR6 
0 
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Wherein 
[0036] R1, R2, R3 and R6 are as de?ned above; 
in the presence of a base and a phosphonate of formula @(IV) 
(XIV) 
O 
)k/ P(O)(OR7)2 R50 
Wherein 
[0037] R5 is as de?ned above and R7 is a Cl-C3 alkyl group. 
[0038] According to a preferred embodiment, said base is 
selected from the group formed by sodium hydride, lithium 
di-iso -propylamine, 1,8-diaZabicyclo [5 .4 .0]undec -7 -ene 
(DBU) and 1,5-diaZabicyclo[4.3.0]non-5-ene (DBN), prefer 
ably sodium hydride. The phosphonate of formula @(IV) 
used is preferably methyl (dimethoxyphosphoryl)acetate. 
[0039] According to a preferred embodiment, the com 
pound of formula @111) is prepared by reacting in the pres 
ence of a base a compound of formula (V 11) 
(v11) 
0 
0 
R30 
R10 
R2 
0 
Wherein 
[0040] R1, R2 and R3 are as de?ned above; 
With a compound of formula (XV) 
RGSeX (xv) 
Wherein 
[0041] R6 is as de?ned above, and 
[0042] X is a halogen selected from C1 and Br. 
[0043] Said base is preferably selected from the group 
formed by sodium hydride, a secondary amine such as mor 
pholine, diethylamine, N-phthalimide or bis(trimethylsilyl) 
amides of alkali metals such as lithium (LiHMDS), sodium 
(NaHMDS) or potassium (KHMDS), preferably sodium 
hydride or morpholine. 
[0044] Phenylselenyl bromide (PhSeBr) is preferably used 
as compound of formula (XV). 
[0045] Said reaction can be carried out folloWing methods 
knoWn in the state of the art. For example, it is possible to add 
the compound of formula @(V) on a solution of sodium 
enolate generated from the compound of formula (V H) (see 
Smith, M. B.; March, J. March ’s Advanced Organic Chemis 
try; John Wiley & Sons: NeW York, 2001. pp.: 548-556.). 
Alternatively, it is possible to prepare a solution comprising 
an amine, for example morpholine, and the compound of 
formula (XV), and then add the compound of formula (Vll) 
on said solution (see Boivin, S.; Outurquin, F.; Paulmier, C. 
Tetrahedron 1997, 53, 16767-16782.). According to a pre 
ferred embodiment, the base used is a chiral secondary amine, 
giving rise to an enantiomerically pure or enantiomerically 
enriched compound of formula (Xlll). Therefore, knoWn 
chiral secondary amines such as proline (see for example 
Vignola, N.; List, B. .I. Am. Chem. Soc. 2004, 126, 450-451) 
alloW obtaining the tWo enantiomers of the compounds of 
formula @111) or enantiomerically enriched mixtures 
thereof, and therefore the compounds of formula (V I), (III) 
and (H), and enantiomerically enriched or enantiomerically 
pure cinatrins C 1 and C3. 
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[0046] Therefore, according to route b), the compounds of 
formula (VI) can be prepared following a synthetic route 
Which comprises 
[0047] (i) reacting a compound of formula (VII) With a 
compound of formula (XV) to obtain a compound of 
formula @111); and 
[0048] (ii) reacting said compound of formula Qilll), in 
the presence of a base, With a phosphonate of formula 
@(IV). 
[0049] Returning to route a) for obtaining the compounds 
of formula general (111), according to a preferred embodi 
ment, the compound of formula (V) is prepared by reacting a 
compound capable of generating ?uoride ions With a com 
pound of formula (X1) 
(X1) 
0 
R10 
Wherein 
[0050] R1, R2 and R3 are as de?ned above, and 
[0051] R4 is a trialkylsilyl group. 
[0052] As can be observed, the epoxide group in the com 
pound of formula Gil) opens regioselectively to form a com 
pound of formula (V). General regioselective opening meth 
ods are knoWn in the art, such as those described in Pujol, B.; 
Sabatier, R.; DrigueZ, P. A.; Doutheau, A. Tetrahedron Lett. 
1992,33, 1447-1450. 
[0053] This opening is performed With a compound 
capable of generating ?uoride ions. Preferably, the hydrof 
luoric acid-pyridine system, hydro?uoric acid in aqueous 
solution or a trihydrogen ?uoride of formula NR3.3HF, 
Wherein R is independently selected from the group consist 
ing of hydrogen and C l-C3 alkyl, is used; more preferably, the 
compound used is triethylamine tris-hydro?uoride (Et3N. 
3HF). 
[0054] Each of the tWo enantiomers of the compounds of 
formula (V) can be obtained by means of the regiospeci?c 
opening of the suitable enantiomer of the compound of for 
mula 0(1), When the latter is prepared by means of asymmet 
ric epoxidation. Alternatively, if the compound of formula 
(X1) is in racemic form, the compound of formula (V) Will 
also be obtained in its racemic form, being able to be used as 
such or separated into each of its enantiomers according to the 
methods Which are common general knowledge. 
[0055] According to a preferred embodiment, the com 
pound of formula Gil) is obtained by reacting an epoxidiZing 
agent With a compound of formula Q() 
(X) 
R10 
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Wherein 
[0056] R1, R2, R3 and R4 are as de?ned above. 
[0057] Non-limiting examples of conditions in Which this 
transformation can be carried out can be found in, for 
example, a) Pujol, B.; Sabatier, R.; DrigueZ, P. A.; Doutheau, 
A. Tetrahedron Lett. 1992, 33, 1447-1450; or b) LoWinger, T. 
B.; Chu, J.; Spence, P. L. Tetrahedron Lett. 1995, 36, 8383 
8386. It is also possible to ?nd a general explanation about 
these reactions in the folloWing references: (a) Smith, M. B.; 
March, J. March ’sAdvanced Organic Chemistry; John Wiley 
& Sons: NeW York, 2001, pp. 1051-1054; (b) Davis, F. A.; 
Sheppard, A. C. J. Org. Chem. 1987, 52, 954-955; or (c) 
Dayan, S.; Bareket,Y.; RoZen, S. Tetrahedron 1999, 55, 3657 
3 664 . According to a preferred embodiment, said epoxidiZing 
agent is selected from the group consisting of m-CPBA, 
2-sulfonyloxaZiridines and the HOF.CH3CN complex; more 
preferably m-CPBA. 
[0058] As mentioned above, it is possible to perform the 
epoxidation of the compound of formula Q() in an asymmet 
ric manner in order to obtain the compound of formula Gil) 
With an enantiomeric excess or in an enantiomerically pure 
manner, opening the route to compounds of formula (II), and 
therefore also to the compounds of formula (la) and (lb), With 
an enantiomeric excess or in an enantiomerically pure man 
ner. 
[0059] Therefore, the present invention also contemplates 
the methods for the asymmetric epoxidation of the com 
pounds of formula Qi) such as those described in the art by 
means of using chiral auxiliaries as described in Walkup, R. 
D.; Obeyesekere, N. U. J. Org. Chem. 1988, 53, 920-923; or 
by means of using chiral catalysts as described in Zhu, Y.; Tu, 
Y.; Yu, H.; Shi, Y. Tetrahedron Lett. 1998, 39, 7819-7822. 
[0060] According to a preferred embodiment, the com 
pound of formula (X) is prepared by reacting a compound of 
formula (V 11) 
(v11) 
0 
0 
R30 
R10 
R2 
0 
Wherein 
[0061] R1, R2 and R3 are as de?ned above; 
With a trialkylsilyl halide or With a trialkylsilyl tri?ate in the 
presence of a base. 
[0062] Non-limiting examples of conditions under Which 
this transformation can be carried out can be found in, for 
example, Dalla,V.; Catteau, J. P. Tetrahedron 1999, 55, 6497 
6510, and the trialkylsilyl groups Which can be used in this 
reaction, as Well as reagents suitable for their introduction, 
are knoWn for the person skilled in the art (for example see 
Greene, T. W.; Wuts, P. G. M. Greene’s Protective Groups in 
Organic Synthesis; John Wiley & Sons: Hoboken, 2007. pp.: 
1 89-196. 
[0063] According to a preferred embodiment, the trialkyl 
silyl group is selected from the group formed by trimethylsi 
lyl, triethylsilyl, tri-iso-propylsilyl, dimethylisopropylsilyl, 
diethylisopropylsilyl, dimethylthexylsilyl, tent-butyldimeth 
ylsilyl and tert-butyldiphenylsilyl; and the preferred halides 
are selected from chlorine and iodine. 
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[0064] The trialkylsilyl group is preferably tert-butyldim 
ethylsilyl; and the preferred trialkylsilyl tri?ate is tert-bu 
tyldimethylsilyl tri?uoromethanesulfonate. 
[0065] The reaction of the compounds of formula (VII) can 
give rise to tWo stereoisomers of the compounds of formula 
(X), according to the stereochemistry of the double bond in 
C2-C3 ((E) or (Z)). For the purposes of the present invention, 
it is irrelevant Which of the tWo stereoisomers is formed. As 
has been mentioned above, it Will be possible to invert the 
stereochemistry of the hydroxyl in the C3 position (for 
example, in compounds of (III) or (V)) by means of the 
Mitsunobu reaction, Which alloWs obtaining any of the enan 
tiomers of the compounds of formula (II), and therefore dif 
ferent stereoisomers of compounds of formula (Ia) and (lb). 
[0066] Therefore, according to route a), the compounds of 
formula (V) can be prepared folloWing the synthetic route 
Which comprises: 
[0067] (i) reacting said compound of formula (VII) With 
a trialkylsilyl halide or With a trialkylsilyl tri?ate in the 
presence of a base to obtain a compound of formula Q(); 
[0068] (ii) reacting said compound of formula Q() with 
an epoxidiZing agent to obtain a compound of formula 
@(I); and 
[0069] (iii) reacting said compound of formula @(I) With 
a compound capable of generating ?uoride ions. 
[0070] As can be seen, in both routes a) and b), the common 
intermediate is a compound of formula (VII). According to a 
preferred embodiment, the compound of formula (VII) is 
prepared by reacting in the presence of a base a compound of 
formula (VIII) 
(VIII) 
RIO 
Y R2 
O 
Wherein 
[0071] R1 and R2 are as de?ned above; 
With an oxalic acid diester of formula (IX) 
(IX) 
0 0R3 
o;\:oR3 
Wherein 
[0072] R3 is as de?ned above. 
[0073] According to a preferred embodiment, said base is 
an inorganic base. Non-limiting examples of conditions 
under Which this transformation can be carried out can be 
found in, for example, DuboWchik, G. M.; Padilla, L.; 
Edinger, K.; Firestone, R. A. .1. Org. Chem. 1996, 61, 4676 
4684. According to a preferred embodiment, said base is 
sodium hydride. 
[0074] As mentioned above, the compounds of formula (Ia) 
and (lb) can be prepared from the compounds of formula (III) 
by means of dihydroxylation folloWed by hydrolysis of the 
compound of formula (II) obtained in the presence of a base 
and subsequent acidi?cation. Therefore, an additional aspect 
of the invention relates to a process for preparing compounds 
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of formula (Ia) and (lb), their stereoisomers, or mixtures 
thereof, or mixtures of the compounds of formula (Ia) and (lb) 
or mixtures of their stereoisomers, Which comprises 
[0075] (i) dihydroxylating the double bond of a com 
pound of formula (III) to obtain a compound of formula 
(II), its stereoisomers, or mixtures thereof; 
[0076] (ii) hydrolyZing said compound of formula (II) in 
the presence of an alkali or alkaline earth metal hydrox 
ide, or of an alkali or alkaline earth metal carbonate; and 
[0077] 
Wherein the R3 and R5 groups can be hydrolyZed under the 
basic conditions of step (ii). 
[0078] As has been described throughout the present docu 
ment, the synthesis of the compounds of formula (II), and 
therefore also of the compounds of formula (Ia) and (lb), can 
be chiral by means of the synthesis of enantiomerically pure 
or enantiomerically enriched intermediates. 
[0079] Therefore, a preferred embodiment of the present 
invention comprises the preparation of compounds of for 
mula (Ia’) and (Ib’), or their enantiomers 
(iii) acidifying the reaction medium; 
(121') 
Wherein 
[0080] R2 is as de?ned above; 
from compounds of formula (111a) and (11a), or their enanti 
omers. 
[0081] As can be observed, the hydrolysis in basic medium 
and subsequent acidi?cation (steps (ii) and (iii)) of the com 
pounds of formula (II) involves the hydrolysis of the carboxy 
ester groups of Which R3 and R5 form part to give rise to the 
corresponding carboxy acids. Therefore, in order to carry out 
the transformation indicated above it is necessary for the 
carboxy esters of Which R3 and R5 form part to be labile in 
basic medium. Without Wishing to be bound by theory, it 
seems that the step (ii) of the process for preparing com 
pounds of formula (Ia) and/or (Ib) involves the formation of a 
triacid, the lactoniZation of the hydroxyl of the C2 position of 
Which With the carboxy acid group of the C4 position (see 
route A in scheme 2) Would generate a compound of formula 
(Ia). In addition, it seems that the acidic medium used in step 
(iii) must alloW the formation of a tertiary carbocation, gen 
erated by means of the loss of the OH group of the C4 position 
of the triester provided by the acidic medium used (see route 
B in scheme 2). The subsequent cycliZation of the carboxy 
acid group of the C2 position With said carbocation in the C4 
position Would generate a compound of formula (Ib). 
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Scheme 2 
[0082] Suitable bases for the hydrolysis of carboxylic 
esters and for opening the ring in the compounds of formula 
(11) (step (i)) are known by the skilled person, such as lithium 
hydroxide, sodium hydroxide, potassium hydroxide, potas 
sium carbonate, cesium carbonate, barium hydroxide. 
[0083] Any protic acid Will alloW closing the cycle to form 
cinatrins C 1 and C3 (step (ii)), the acid used is preferably 
hydrochloric acid. 
[0084] Similar conditions for this reaction can be found in 
CuZZupe, A. N.; Di Florio, R.; White, J. M.; RiZZacasa, M. A. 
Org. Biomol. Chem. 2003, 1, 3572-3577. 
[0085] Said process can give rise to mixtures of the corre 
sponding compounds of formula (la) and (lb), Which can be 
separated into the corresponding essentially pure compounds 
by means of methods Which are common general knowledge 
(for example, chromatographic column or recrystallization). 
[0086] Alternatively, it is possible to directly obtain the 
compounds of formula (la) from compounds of formula (II) 
and (111) without needing to form compounds of formula (lb). 
This can be achieved by transforming the carboxy ester 
groups of Which R3 and R5 form part into carboxy acid groups 
under conditions Which do not give rise to the opening of the 
lactone and therefore under conditions Which do not alloW the 
formation of the aforementioned triacid (see Scheme 2), the 
origin of the formation of both compounds of formula (la) and 
of formula (lb). Consequently, an additional aspect of the 
present invention is a process for preparing a compound of 
formula (la) 
la 
0 
OH 
0 
R2 
cozrr 
H020 OH 
y (la) 
Carbocation 
(1b) 
Wherein 
[0087] R2 is a Clo-Cl5 alkyl group; 
its stereoisomers, or mixtures thereof, 
Which comprises 
(i) dihydroxylating the double bond of a compound of for 
mula (III), as de?ned above, to obtain a compound of formula 
(11) 
(H) 
O 
OH 
0 
R2 
CO2R3 
R5020 OH 
Wherein 
[0088] R2, R3 and R5 are as de?ned above; 
its stereoisomers, or mixtures thereof; and 
(ii) transforming under non-basic conditions the carboxy 
ester groups of the lactone ring of the compound of formula 
(II) to obtain the corresponding carboxy acid groups. 
[0089] Conditions under Which it is possible to perform the 
transformation of step (ii) are generally those in Which it is 
possible to transform the carboxy ester groups of Which R3 
and R5 form part into carboxy acid groups under conditions 
Which do not given rise to the opening of the lactone. Carboxy 
ester groups Which can be transformed into carboxy acid 
groups under non-basic conditions (for example, by hydro 
genation or in acidic medium) are knoWn for the person 
skilled in the art. Non-limiting examples are esters derived 
from p-methoxybenZyl, l-phenyl-ethyl, or trityl. 
[0090] According to a preferred embodiment, R3 and R5 are 
benZyl groups (i(CH)2-phenyl). The hydrogenation of a 
compound of formula (11) wherein R3 and R5 are benZyl only 
provides a compound of formula (la), Without signi?cant 
amounts of compounds of formula (lb) being obtained. For 
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similar conditions, see for example the transformation of 
compound 20 into compound 14 in Evans, D. A.; Trotter, B. 
W.; BarroW, J. C. Tetrahedron 1997, 53, 8779-8794, incorpo 
rated in its entirety to the description of the present invention. 
According to another preferred embodiment, it is possible for 
the R3 and R5 groups to be labile in acidic medium. The 
acidi?cation of the reaction medium removes said R3 and R5 
groups to form the corresponding carboxy acids, Without 
opening the lactone of the compound of formula (II), there 
fore providing a compound of formula (Ia), Without the for 
mation of signi?cant amounts of a compound of formula (lb) 
being observed. For example, if R3 and R5 are t-butyl, it is 
possible to obtain the corresponding carboxy acids in acidic 
medium (for example, With tri?uoroacetic acid) Without the 
ring being opened. For example, see the transformation of 
compound 19 into compound 13 in Evans, D. A.; Trotter, B. 
W.; Barrow, J. C. Tetrahedron 1997, 53, 8779-8794. 
[0091] According to a preferred embodiment, R2 is n-dode 
cyl. According to another preferred embodiment, R1 is a 
Cl-C3 alkyl, preferably methyl. According to another pre 
ferred embodiment, R3 is a Cl-C3 alkyl, preferably methyl. 
According to another preferred embodiment, R5 is a C l-C3 
alkyl, preferably methyl. 
Intermediates of the Process of the Invention and Use 
Thereof. 
[0092] In vieW of What has been seen up until noW, the 
compounds of formula (II) are intermediates in the synthesis 
of the present invention. Therefore, an additional aspect of the 
invention relates to a compound of formula (II) 
OH 
O 
CO2R3 
R5020 on 
Wherein 
[0093] R2 is selected from a Clo-Cl5 alkyl group; 
[0094] R3 and R5 are independently selected from a substi 
tuted or unsubstituted C l-C2O alkyl group; 
its stereoisomers, especially enantiomers, or mixtures 
thereof; 
With the proviso that the compound of formula (II) is not 
MeOZC on 
[0095] The use of the compounds of formula (II) de?ned 
above for the synthesis of compounds of formula (Ia) or (Ib), 
their stereoisomers, or mixtures thereof, as Well as mixtures 
of compounds of formula (Ia) and (lb) or mixtures of their 
stereoisomers, is also an aspect of the present invention. 
[0096] Other aspects of the present invention relate to com 
pounds of formula (III), (V), (VI), (VII), (X), (XI) and @(III), 
intermediates in the synthesis of the invention, their stereoi 
somers, or mixtures thereof. 
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[0097] According to a preferred embodiment, R2 in the 
compounds of formula (III), (V), (VI), (VII), Qi), (XI) and 
@(III) is n-dodecyl. According to another preferred embodi 
ment, R1 is methyl. According to another preferred embodi 
ment, R3 is methyl. According to another preferred embodi 
ment, R5 is methyl. 
[0098] The use of the compounds of formula (III), (V), 
(VI), (VII), Q(), @(I) and @(III) for the synthesis of com 
pounds of formula (Ia) or (Ib), their stereoisomers, or mix 
tures thereof, as Well as mixtures of compounds of formula 
(Ia) and (lb) or mixtures of their stereoisomers, is also an 
aspect of the present invention. 
DEFINITIONS 
[0099] For the purpose of facilitating the understanding of 
the present invention, the meanings of several terms and 
expressions as they are used in the context of the invention are 
included herein. 
[0100] “Alkyl” refers to a radical With a linear or branched 
hydrocarbon chain Which consists of carbon and hydrogen 
atoms, Which does not contain unsaturations and Which is 
attached to the rest of the molecule by means of a single bond. 
The number of carbon atoms of the alkyl group is speci?ed in 
each case. For example, When “C1-C4 alkyl” is indicated it 
refers to an alkyl group of one, tWo, three of four carbon 
atoms, i.e., methyl, ethyl, propyl, isopropyl or n-butyl. For 
example, When “Clo-C15 alkyl” is indicated it refers to an 
alkyl group often, eleven, tWelve, thirteen, fourteen or ?fteen 
carbon atoms, such as decyl, undecyl, dodecyl, tridecyl, tet 
radecyl or pentadecyl. 
[0101] “Halide” or “halogen” means *F, *Cl, *Br or 
*1; 
[0102] A “stereoisomer” in the present application refers to 
compounds formed by the same atoms attached by the same 
sequence of bonds but having different three-dimensional 
structures Which are not interchangeable. 
[0103] “Enantiomer” is understood as the mirror image of a 
stereoisomerically pure compound. For the purposes of the 
invention, an enantiomer can be considered as a mixture of 
tWo enantiomers having an enantiomeric excess greater than 
95%, preferably greater than 98%, more preferably greater 
than 99%, more preferably greater than 99.5%. 
[0104] “Bn” means benZyl (i(CH2)-phenyl). 
[0105] “Trialkylsilyl” is understood as a radical of formula 
iSi(R')(R")R"', Wherein each of R', R" and R'" are indepen 
dently selected from among a phenyl group and a C l-C6 alkyl 
group. Non-limiting examples of trialkylsilyl groups can be 
trimethylsilyl, triethylsilyl, tri-iso-propylsilyl; dimethyliso 
propylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, tert 
butyldimethylsilyl, tert-butyldiphenylsilyl. 
[0106] The references of the present document to substi 
tuted groups in the compounds of the present invention refer 
to the speci?ed moiety Which can be substituted in one, tWo or 
three available positions With one, tWo, three suitable groups, 
Which are independently selected from the group consisting 
of cyano; alkanoyl, such as a Cl-C6 alkanoyl group, such as 
acyl and the like; carboxamido (i(C:O)NH2); trialkylsilyl; 
carbocyclic aryl having 6 or more carbons, particularly phe 
nyl or naphthyl and (C l-C3)alkylaryl such as tolyl. As a non 
limiting example, “substituted alkyl” includes groups such as 
cyanoethyl, acetylmethyl, carboxamidomethyl 
(iCHzCONHz), 2-trimethylsilylethyl, benZyl, diphenylm 
ethyl. 
[0107] “Aryl” refers to a C6-Cl4 aromatic hydrocarbon 
radical such as phenyl, naphthyl or anthracyl. 
[0108] Unless otherWise indicated, the compounds of the 
invention also refer to those including compounds Which 
differ only in the presence of one or more isotopically 
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enriched atoms. For example, the compounds having the 
present structures, With the exception of the substitution of a 
hydrogen With a deuterium or With tritium, or the substitution 
of a carbon With a 13 C- or l4C-enriched carbon, are Within the 
scope of this invention. 
[0109] The following examples illustrate different embodi 
ments of the invention and must not be considered as limiting 
the scope thereof. 
EXAMPLES 
General Methods and Materials 
[0110] All the reactions Were performed under an argon 
atmosphere, except those indicated in each case. The solvents 
used Were distilled and dried under an argon atmosphere. The 
reagents and solvents used are from the companies Aldrich, 
Fluka, Merck, Sigma, Acros, Lancaster, SDS or Scharlau, and 
Were puri?ed by usual processes When necessary. The puri 
?cation of the reaction products Was performed by column 
chromatography under pressure (?ash chromatography), 
using 60 Merck silica gel (With a 230-400 mesh particle siZe) 
as a stationary phase. 
[0111] The (fully decoupled) 1H and 13 C nuclear magnetic 
resonance spectra Were performed at room temperature in the 
solvent indicated in each case (CDCl3 and CD3OD) using the 
folloWing apparatuses: Varian Gemini-200 (200 MHZ), 
Varian lNOVA-300 (300 MHZ), Bruker Avance-300 (300 
MHZ) and Varian lNOVA-400 (400 MHZ). The values of the 
chemical shifts are expressed in parts per million (6, ppm), 
using as an internal reference the residual signal of the sol 
vent: CDCl3, 7.26 ppm (lH-NMR) and 77.0 ppm (13C 
NMR); CD3OD, 3.31 ppm (lH-NMR) and 49.0 ppm (13C 
NMR). The 1H-NMR spectra are described indicating the 
number of protons and the apparent multiplicity of each sig 
nal. The coupling constants (J) are the apparent ones and are 
expressed in HZ. The folloWing abbreviations have beenused: 
s (singlet), d (doublet), t (triplet), c (quadruplet), q (quintu 
plet) and m (multiplet). 
[0112] The melting points (m.p.) Were measured in a 
Reichert brand Ko?er microscope. The infrared (IR) spectra 
Were recorded in the Perkin-Elmer spectrophotometer mod 
els 681 and FT-IR Spectrum One. The loW resolution mass 
spectra (LRMS) Were recorded: (1) by direct injection of the 
sample into a HeWlett Packard 5973 MSD spectrophotometer 
using the electron impact (El) ioniZation technique; or (2) in 
a HeWlett Packard LCMS 1100 MSD spectrophotometer (an 
HPLC-coupled quadrupole analyZer) using the electrospray 
chemical ioniZation technique (APl-ES) in positive or nega 
tive modes. The elemental analyses (E.A.) Were performed 
With the Perkin-Elmer 240C and Heraus CHN4O-Rapid 
analyZers. 
[0113] Unless otherWise indicated, all the products shoWn 
in the examples are racemic (rac). 
Example 1 
Preparation of methyl rac-(S)-3-(methoxycarbonyl) 
2-oxopentadecanoate 
THF, MeOH 
[0114] 
/OW 
O 
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0 \O 
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[0115] MeOH (0.5 ml) Was added at 0° C. to a suspension of 
NaH (1.08 g, 45.3 mmoles) in THF (19.5 ml). The mixture 
Was stirred until it reached room temperature. Then, methyl 
myristate (10 g, 41.2 mmoles) and dimethyl oxalate (4.87 g, 
41.2 mmoles) Were added. The resulting mixture Was heated 
under re?ux for 3 hours. After that time, H20 (19 ml) Was 
added at 0° C. and the mixture Was neutraliZed With an aque 
ous solution of 10% HCl. The phases Were separated, and the 
aqueous phase Was extracted With AcOEt (3><10 ml). The 
organic phase Was dried With anhydrous Na2SO4, ?ltered and 
the solvent Was removed under reduced pressure. The product 
Was puri?ed by a chromatographic column (hexane/AcOEt, 
20:1), obtaining (8.61 g, yield 64%) methyl rac-(S)-3-(meth 
oxycarbonyl)-2-oxopentadecanoate, as a transparent oil. 
[0116] 1H-NMR (300 MHZ, CDCl3). 6 4.01 (1H, t, J:6.9 
HZ, H-3), 3.88 (3H, s, ADCH3), 3.71 (3H, s, ADCH3), 1.88 
(2H, m, H-4), 1.24 (20H, m, %H2i), 0.86 (3H, m, iCH3). 
Example 2 
Preparation of methyl 2-(tert-butyldimethylsilyloxy) 
3-(methoxycarbonyl) -2 -pentadecenoate 
[0117] 
CHZCIZ, RT 
0 
\O OTBDMS 
o 
/ 9 
o 
[0118] TBDMSOTf(1.84 g, 6.96 mmoles) Was added at 0° 
C. to a solution of methyl rac-(S)-3-(methoxycarbonyl)-2 
oxopentadecanoate (1.90 g, 5.80 mmoles) and Et3N (1.17 g, 
11.6 mmoles) in CH2Cl2 (48 ml). The mixture Was stirred at 
room temperature for 24 hours. After that time, the solvent 
Was removed under reduced pressure. The product Was puri 
?ed by a chromatographic column (hexane/AcOEt, 12:1), 
obtaining (2.09 g, yield 82%) methyl 2-(tert-butyldimethyl 
silyloxy)-3-(methoxycarbonyl)-2-pentadecenoate, as a trans 
parent oil. 
[0119] IR (NaCl): v 3388, 2943, 2927, 2854, 1738, 1716, 
1627,1432, 1310, 1204, 1129, 1097, 840, 811, 784 cm_l. 
US 2011/0275838 A1 
[0120] 1H-NMR (300 MHZ, CDCl3). 6 3.79 (3H, s, 
iOCH3), 3.71 (3H, s, iOCH3), 2.29 (2H, m, %H2i), 
1.32 (20H, m, iCHZi), 0.94 (9H, s, tert-BuSi), 0.87 (3H, m, 
iCH3), 0.17 (6H, s, (CH3)2Si). 
[0121] l3C-NMR (75 MHZ, CDCl3). 6 182.3, 168.6, 165.8, 
118.2, 52.2, 51.7,31.9,29.6,29.5,29.4,29.3,28.2,26.0,25.4, 
22.6,18.3,14.1,—4.6. 
[0122] LRMS (El): m/Z 442 (M", 0), 441 (M+—1, 1), 427 
(3), 411 (3), 385 (100). 
[0123] EA. (C24H46O5Si). Found: C, 65.00, H, 10.50. Cal 
culated: C, 65.11, H, 10.47. 
Example 3 
Preparation of methyl rac-(2R,3R)-2-(tert-butyldim 
ethylsilyloxy)-2,3-epoxy-3-(methoxycarbonyl)-pen 
tadecanoate 
[0124] 
O 
OTBDMS _ \O m CPBA 
CHZCIZ, RT 
O 
/ 9 
O 
[0125] m-CPBA (7.77 g, 45.0 mmoles) Was added to a 
solution of methyl 2-(tert-butyldimethylsilyloxy)-3-(meth 
oxycarbonyl)-2-pentadecenoate (9.96 g, 22.5 mmoles) in 
CH2Cl2 (129 ml). The mixture Was stirred at room tempera 
ture for 5 days. After that time, Celite Was added and the 
solvent Was removed under reduced pressure. The product 
Was puri?ed by a chromatographic column (hexane/AcOEt, 
10:1), obtaining (9.96 g, yield 96%) methyl rac-(2R,3R)-2 
(tert-butyldimethylsilyloxy)-2,3-epoxy-3-(methoxycarbo 
nyl)-pentadecanoate, as a transparent oil. 
[0126] IR (NaCl): v 3389, 2952, 2928, 2856, 1758, 1462, 
1440,1401,1362,1307,1255,1199,1165,1100,1004,843, 
785 cm_l. 
[0127] 1H-NMR (300 MHZ, CDCl3). 6 3.76 (3H, s, 
iOCH3), 3.75 (3H, s, ADCH3), 2.07 (1H, m, H-4), 1.78 
(1H, m, H-4), 1.46 (2H, m, H-5), 1.24 (18H, Shroud, 
iCH2i), 0.91 (9H, s, tert-BuSi), 0.87 (3H, m, %H3), 0.20 
(3H, s, (CH3)2Si), 0.15 (3H, s, (CH3)2Si). 
[0128] l3C-NMR (75 MHZ, CDCl3). 6 168.1, 166.4, 82.0, 
68.0, 52.8, 52.4, 31.8, 29.5, 29.5, 29.4, 29.3, 29.3, 28.1, 25.3, 
24.4, 22.6, 17.9, 14.0, —4.0, —4.6. 
[0129] LRMS (El): m/Z 458 (M", 0), 443 (2), 427 (0), 401 
(66), 399 (9), 341 (10), 313 (3), 281 (2), 233 (100). 
[0130] EA. (C24H46O6Si). Found: C, 63.00, H, 10.00. Cal 
culated: C, 62.84, H, 10.11. 
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Example 4 
Preparation of methyl rac-(R)-3-hydroxy-3-(meth 
oxycarbonyl)-2-oxopentadecanoate 
[0131] 
[0132] Et3N.(HF)3 (0.95 g, 5.90 mmoles) Was added to a 
solution of methyl rac-(2R,3R)-2-(tert-butyldimethylsily 
loxy)-2,3-epoxy-3-(methoxycarbonyl)pentadecanoate (9.01 
g, 19.66 mmoles) in MeOH (180 ml). The mixture Was stirred 
at room temperature for 2 .5 hours. After that time, AcOEt Was 
added, and the mixture Was Washed With H2O (2><3 ml), dried 
With anhydrous Na2 SO 4, ?ltered and the solvent Was removed 
under reduced pressure. The product, methyl rac-(R)-3-hy 
droxy-3-(methoxycarbonyl)-2-oxopentadecanoate, Was used 
in the following step Without purifying. 
[0133] IR (NaCl): v 3473, 2955, 2925, 2854, 1740, 1438, 
1259,1138,1074 cm“. 
[0134] 1H-NMR (300 MHZ, CDCl3). 6 3.87 (3H, s, 
ADCH3), 3.84 (3H, s, iOCH3), 1.95 (2H, m, H-4), 1.24 
(20H, Shroud, iCHZi), 0.87 (3H, t, 1:65 HZ, %H3). 
[0135] l3C-NMR (75 MHZ, CDCl3). 6 188.5, 170.7, 162.0, 
80.5, 53.6, 53.0, 33.9, 31.8, 29.5, 29.5, 29.5, 29.4, 29.2, 22.6, 
22.4, 14.0. 
[0136] LRMS (El): m/Z 345 (M++1, 0), 313 (1), 286 (0), 
257 (14), 225 (0), 197 (100). 
Example 5 
Preparation of methyl rac-(2Z,4R)-4-hydroxy-3,4-bis 
(methoxycarbonyl) —2 —hexadecenoate 
[0137] 
US 2011/0275838 A1 
[0138] [(Methoxycarbonyl)methylene]triphenylphospho 
rane (16.43 g, 49.12 mmoles) Was added to a solution of 
methyl rac-(R)-3-hydroxy-3-(methoxycarbonyl)-2-oxopen 
tadecanoate (6.77 g, 19.65 mmoles), obtained previously, in 
CH2Cl2 (186 ml). The mixture Was stirred at room tempera 
ture for 48 hours. After that time, Celite Was added and the 
solvent Was removed under reduced pressure. The product 
Was puri?ed by a chromatographic column (hexane/AcOEt, 
7:1), obtaining (7.60 g, yield 97%) methyl rac-(2Z,4R)-4 
hydroxy-3,4-bis(methoxycarbonyl)-2-hexadecenoate as a 
colorless oil. 
[0139] IR (NaCl): v 3494, 2925, 2854, 1733, 1646, 1436, 
1349,1256,1199,1168,1019 cm_l' 
[0140] 1H-NMR (300 MHZ, CDCl3). 6 6.26 (1H, s, H-2), 
3.80 (3H, s, ADCH3), 3.80 (3H, s, ADCH3), 3.71 (3H, s, 
iOCH3), 3.67 (1H, s, iOH), 1.91 (2H, m, iCHZi), 2.43 
(2H, m, iCHZi), 1.22 (18H, m, iCHZi), 0.85 (3H, t, 
1:68 HZ, iCH3). 
[0141] l3C-NMR (75 MHZ, CDCl3). 6 173.0, 166.8, 164.9, 
151.0, 120.3, 77.7, 53.6, 52.4, 52.0, 37.5, 31.8, 31.5, 29.5, 
29.5, 29.4, 29.3, 29.3, 29.2, 23.1, 22.6, 14.0. 
[0142] LRMS (El): m/Z 401 (M++1, 3), 383 (1), 369 (8), 
341 (28), 309 (100), 249 (18), 197 (18). 
[0143] EA. (C2IH36O7). Found: C, 63.00, H, 9.00; Calcu 
lated: C, 62.98, H, 9.06. 
Example 6 
Preparation of [(methoxycarbonyl)methylene]-triph 
enylpho sphorane 
[0144] 
o 
/ Y\Br PPh3 —> 
O toluene, RT 
0 
/ W PPh3Br 
o 
[0145] Methyl bromoacetate (5.3 g 34.6 mmoles, 1 eq.) Was 
added to a solution ofPPh3 (9.52 g, 36.3 mmoles, 1.05 eq.) in 
toluene (20 ml). The mixture Was stirred at room temperature 
for 24 hours. A suspension Was gradually formed, Which Was 
?ltered under vacuum and Washed With toluene (3x10 ml). 
The product, [(methoxycarbonyl)methyl]triphenylphospho 
nium bromide, Was used in the folloWing step Without puri 
fying. 
[0146] 1H-NMR (200 MHZ, CDCl3). 6 8.00-7.60 (15H, m, 
AriH), 5.62 (1H, d, JP’H:15.5 HZ, H-1), 3.61 (3H, s, 
iOCH3). 
[0147] An aqueous solution of 1.15 N NaOH (60 ml) Was 
added at room temperature to a solution of [(methoxycarbo 
nyl)methyl]triphenylphosphonium bromide (14.3 g, 34.6 
mmoles, 1 eq.), obtained previously, in CH2Cl2 (90 ml). The 
resulting mixture Was stirred vigorously at room temperature 
for 2 hours. After that time, the phases Were separated. The 
aqueous phase Was extracted With CH2Cl2 (3x10 ml). The 
organic phase Was dried With anhydrous MgSO4, ?ltered and 
the solvent Was removed under reduced pressure, obtaining 
(10.5 g, yield 90%) [(methoxycarbonyl)methylene]-triph 
enylphosphorane as a White solid. 
[014s] 1H-NMR (200 MHZ, CDC13). 6 7.61 (15H, m, 
AriH), 5.62 (1H, m, H-1), 3.50 (3H, s, wcm). 
NaOH 
CHZCIZ, RT 
O 
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Example 7 
Preparation of methyl rac-(R)-3 -(phenylselenyl) -3 - 
(methoxycarbonyl) -2-oxopentadecanoate 
Method A 
[0149] 
NaH, BrS ePh 
4>
THF, RT 
O 
O \O 
O ~. / "1,” M 
SePh 
O 
[0150] A solution of methyl rac-(S)-3-(methoxycarbonyl) 
2-oxopentadecanoate (6 g, 18.26 mmoles) in THF (17 ml) 
Was added to a suspension of NaH (0.482 g, 20.09 mmoles) in 
THF (34 ml). The mixture Was stirred at room temperature 
until H2 Was no longer evolved (10 minutes). Then, the mix 
ture Was cooled at 00 C. and a solution of BrSePh (4.74 g, 
20.09 mmoles) in THF (17 ml) Was added. The resulting 
mixture Was stirred at room temperature for 24 hours. After 
that time, H20 (50 ml) Was added. The phases Were separated, 
and the aqueous phase Was extracted With AcOEt (3x30 ml). 
The organic phase Was dried With anhydrous Na2SO4, ?ltered 
and the solvent Was removed under reduced pressure. The 
product Was puri?ed by a chromatographic column (hexane/ 
AcOEt, 10:1), obtaining (5.63 g, yield 65%) methyl rac-(R) 
3-(phenylselenyl)-3-(methoxycarbonyl)-2-oxopentade 
canoate, as a broWn oil. 
Method B 
[0151] 
O 
\O O BrSePh, morpholine 
CHZCIZ, RT 
0 / ‘HI/M 
O 
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[0152] Morpholine (0.221 g, 2.54 mmoles) Was slowly 
added at room temperature to a solution of BrSePh (0.300 g, 
1.27 mmoles) in CH2Cl2 (12 ml). The resulting mixture Was 
stirred at room temperature for 15 minutes. Then, a solution 
of methyl rac-(S)-3-(methoxycarbonyl)-2-oxopentade 
canoate (0.417 g, 1.27 mmoles) in CH2Cl2 (2 ml) Was added. 
The resulting mixture Was stirred at room temperature for 24 
hours, during Which time a solid in suspension gradually 
appeared. After that time, the solid Was ?ltered under vacuum 
over Celite, and the solvent Was removed under reduced pres 
sure. The product Was puri?ed by a chromatographic column 
(hexane/AcOEt, 10: 1), obtaining (0.368 g, yield 60%) methyl 
rac-(R)-3-(phenylselenyl)-3-(methoxycarbonyl)-2-oxopen 
tadecanoate, as a broWn oil. 
[0153] IR (NaCl): v 3057, 2925, 2854, 1736, 1713, 1577, 
1438, 1299, 1232, 1129, 1064, 1020, 999, 743, 692 cm_l. 
[0154] 1H-NMR (200 MHZ, CDCl3). 6 7.36 (5H, m, 
AriH), 3.95 (3H, s, ADCH3), 3.81 (3H, s, iOCH3), 1.70 
(2H, m, iCHZi), 1.43-1.24 (20H, m, %H2i), 0.88 (3H, 
m, 4CH3). 
[0155] l3C-NMR (50 MHZ, CDCl3). 6 179.6, 168.3, 161.2, 
137.8, 130.1, 129.3, 129.0, 124.6, 64.9, 53.3, 53.2,31.6,30.7, 
29.2, 29.0, 27.0, 25.4, 24.6, 24.3, 22.5, 22.2, 20.8, 14.0. 
[0156] LRMS (El): m/Z 484 (M++1, 96), 426 (3), 397 (100), 
365 (60), 337 (50), 269 (14), 235 (12), 157 (55). 
[0157] EA. (C24H36O5Se). Found: C, 59.70, H, 7.30. Cal 
culated: C, 59.62, H, 7.50. 
Example 8 
Reaction of methyl rac-(R)-3-(phenylselenyl)-3 
(methoxycarbonyl)-2-oxopentadecanoate With 
methyl (dimethoxyphosphoryl)acetate 
[0158] 
— 
O I THF, RT 
/ SePh 
O 
[0159] A solution of methyl (dimethoxyphosphoryl)ac 
etate (2.33 g, 12.8 mmoles) in THF (8 ml) Was added to a 
suspension of NaH (0.307 g, 12.8 mmoles) in THF (91 ml). 
The mixture Was stirred at room temperature until H 2 Was no 
longer evolved (10 minutes). Then, a solution of methyl rac 
(R)-3-(phenylselenyl)-3-(methoxycarbonyl)-2-oxopentade 
canoate (5.63 g, 11.64 mmoles) in THF (8 ml) Was added. The 
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resulting mixture Was stirred at room temperature for 24 
hours: After that time, the solvent Was removed under reduced 
pressure. The product Was puri?ed by a chromatographic 
column (hexane/AcOEt, 15:1), obtaining (4.53 g, yield 72%) 
a mixture in a 5:2 ratio of methyl rac-(E,R)-2-(phenylsele 
nyl)-3,4-bis(methoxycarbonyl)-3-hexadecenoate (trans, 
51%) and methyl (Z)-3,4-bis(methoxycarbonyl)-3-hexade 
cenoate (cis, 21%), as a broWn oil. IR (NaCl): v 2925, 2854, 
1733,1632,1577,1458,1435,1313,1268,1199,1158,1125, 
1075, 1001, 742, 693 cm_l. 
[0160] 1H-NMR (200 MHZ, CDCl3). 6 7.39 (5H, m, AriH 
trans), 4.64 (1H, s, H-2 trans), 3.71 (3H, s, iOCH3 cis), 3.69 
(3H, s, 4OCH3 trans), 3.68 (3H, s, 4OCH3 trans), 3.67 (3H, 
s, 4OCH3 trans), 3.65 (3H, s, 4OCH3 cis), 3.61 (3H, s, 
4OCH3 cis), 3.33 (2H, s, H-2 cis), 2.23 (2H, m, H-5 cis), 1.83 
(2H, m, H-5 trans), 1.13 (20H, m, 4CH2i trans, cis), 1.17 
(20H, m, 4CH2i trans, cis), 0.79 (3H, m, ‘CH3 trans), 
0.76 (3H, m, ‘CH3 cis). 
[0161] l3C-NMR (50 MHZ, CDCl3). 6 169.9, 169.0,166.2, 
146.1, 143.1, 136.1, 129.8, 129.0, 128.8, 125.2, 52.9, 52.2, 
52.1, 43.2, 33.5, 31.7, 31.2, 30.4, 29.4, 29.4, 29.3, 29.1, 29.1, 
29.0, 27.3, 22.5, 20.8, 14.0, 13.9. 
[0162] LRMS (El): m/Z 540 (M++1, 6), 508 (33), 383 (12), 
351 (100), 291 (8), 197 (25). 
Example 9 
Preparation of methyl rac-(Z,R)-4-hydroxy-3,4-bis 
(methoxycarbonyl) -2 -hexadecenoate 
[0163] 
Pyridine, HZOZ 
CHZCIZ, RT 
[0164] An aqueous solution of 33% H2O2 (5.99 ml) Was 
added to a solution of methyl rac-(E,R)-2-(phenylselenyl)-3, 
4-bis(methoxycarbonyl)-3 -hexadecenoate (trans) (4.53 g, 
8.39 mmoles) and pyridine (1 .32 g, 16.79 mmoles) in CH2Cl2 
(70 ml). The mixture Was stirred at room temperature for 24 
hours. After that time, the solvent Was removed under reduced 
pressure. The residue Was dissolved in AcOEt (30 ml), and 
H20 (30 ml) Was added. The phases Were separated, and the 
aqueous phase Was extracted With AcOEt (3><10 ml). The 
organic phase Was dried With anhydrous Na2SO4, ?ltered and 
the solvent Was removed under reduced pressure. The product 
Was puri?ed by a chromatographic column (hexane/AcOEt, 
10:1), obtaining (2.2 g, yield 65%) methyl rac-(Z,R)-4-hy 
droxy-3,4-bis(methoxycarbonyl)-2-hexadecenoate as a col 
orless oil. 
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[0165] IR (NaCl): v 3494, 2925, 2854, 1733, 1646, 1436, 
1349,1256,1199,1168,1019 cm_l. 
[0166] 1H-NMR (300 MHZ, CDC13). s 6.26 (1H, s, H-2), 
3.80 (3H, s, wcH3), 3.80 (3H, s, wcH3), 3.71 (3H, s, 
iOCH3), 3.67 (1H, s, 40H), 1.91 (2H, m, iCHZi), 2.43 
(2H, m, icHr), 1.22 (18H, m, icHr), 0.85 (3H, 1, 
1:68 HZ, iCH3). 
[0167] l3c-NMR (75 MHZ, CDC13). 6 173.0, 166.8, 164.9, 
151.0, 120.3, 77.7, 53.6, 52.4, 52.0, 37.5, 31.8, 31.5, 29.5, 
29.5, 29.4, 29.3, 29.3, 29.2, 23.1, 22.6, 14.0. 
[0168] LRMS (E1): m/Z 401 (M++1, 3), 383 (1), 369 (8), 
341 (28), 309 (100), 249 (18), 197 (18). 
[0169] BA. (c21H36o7). Found: c, 63.00, H, 9.00. Calcu 
lated: c, 62.98, H, 9.06. 
Example 10 
Preparation of rac-(3R,4S,5S)-3,4-dihydroxy-3 
dodecyl-4,5 -bis(methoxycarbonyl)tetrahydro -2 -fura 
none (IV) 
[0170] 
OsO4, NMO 
—> 
acetone/H2O RT 
[0171] NMO (1.21 g, 9.99 mmoles) and OsO4 (2.5% in 
tert-BuOH, 0.019 g, 0.075 mmoles) Were added to a solution 
of methyl rac-(Z,R)-4-hydroxy-3,4-bis(methoxycarbonyl) 
2-hexadecenoate (1 g, 2.50 mmoles) in a 5:1 acetone/H2O 
mixture (10.2 ml). The mixture Was stirred at room tempera 
ture for 2 days. After that time, an aqueous solution of 10% 
Na2S2O3 (0.2 ml) Was added. The mixture Was ?ltered 
through silica gel With MeOH and the solvent Was removed 
under reduced pressure. The product Was puri?ed by a chro 
matographic column (hexane/AcOEt, 3:1), obtaining (0.670 
g, yield 67%) rac-(3R,4S,5S)-3,4-dihydroxy-3-dodecyl-4,5 
bis(methoxycarbonyl)tetrahydro-2-furanone (IV) as a White 
solid. 
[0172] mp: 74-760 C. 
[0173] IR (KBr): v 3400, 3339, 2956, 2918, 2851, 1785, 
1775,1714,1467,1445,1364,1307,1226,1155,1133,1061 
cm_l. 
[0174] 1H-NMR (200 MHZ, CDCl3). 6 5.21 (1H, s, H-5), 
3.87 (3H, s, ADCH3), 3.78 (3H, s, ADCH3), 3.56 (1H, 
shroud, ADH), 2.90 (1H, shroud, ADH), 1.80 (2H, m, H-6), 
1.21 (20H, Shroud, iCHZi), 0.83 (3H, m, iCH3). 
[0175] 1H-NMR (300 MHZ, DMSO-d6). 6 6.74 (1H, s, 
iOH), 6.41 (1H, s, iOH), 5.50 (1H, s, H-5), 3.72 (3H, s, 
iOCH3), 3.65 (3H, s, ADCH3), 1.68 (2H, m, H-6), 1.39 
(2H, m, H-7), 1.23 (18H, Shroud, iCHzi), 0.84 (3H, m, 
iCH3). 
12 
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[0176] l3c-NMR (50 MHZ, CDC13). 6 173.9, 170.6, 166.4, 
81.0, 78.5, 54.0, 52.7, 31.7, 29.6, 29.5, 29.4, 29.2, 29.2, 22.5, 
215,139. 
[0177] LRMS (E1): m/Z 402 (M, 0), 315 (2), 285 (2), 234 
(2), 216 (0), 197 (11), 160 (30), 101 (100). 
[0178] BA. (C2OH34O8). Found: c, 59.70, H, 8.50. Calcu 
lated: c, 59.68, H, 8.51. 
Example 11 
Reaction of rac-(3R,4S,5S)-3,4-dihydroxy-3-dode 
cyl-4,5-bis(methoxycarbonyl)tetrahydro-2-?1ranone 
With LiOH/HCl 
[0179] 
LiOH 
THF/HZO, RT 
[0180] An aqueous solution of 1N LiOH (0.104 g, 2.48 
mmoles, 2.5 ml) Was added to a solution of rac-(3R,4S,5S) 
3 ,4 -dihydroxy-3 -dodecyl-4 , 5 -bis (methoxycarbonyl)tetrahy 
dro-2-furanone (IV) (0.050 g, 0.12 mmoles) in THF (5 ml). 
The mixture Was stirred at room temperature for 2 hours. 
After that time, the phases Were separated. The aqueous phase 
Was Washed With AcOEt (2><2 ml), treated With an aqueous 
solution of 10% HCl (until acidic pH) and extracted With 
AcOEt (3><3 ml). The extracts Were dried With anhydrous 
Na2SO4, ?ltered and the solvent Was removed under reduced 
pressure, obtaining (0.026 g, yield 56%) a mixture in a 1:1 
ratio of rac-(3R,4S,5S)-3,4-dihydroxy-3-dodecyl-4,5-dicar 
boxytetrahydro-2-furanone (Cinatrin C3) and rac-(3S,4S, 
5R)-3,4-dihydroxy-5-dodecyl-4,5-dicarboxytetrahydro-2 
furanone (Cinatrin C l) as a White solid. 1H-NMR (300 MHZ, 
CD3OD). 6 5.39 (1H, s, H-5, Cinatrin C3), 4.70 (1H, s, H-3 
CinatrinCl), 2.16 (1H, m, H-6 CinatrinCl), 1.82 (2H, m, H-6 
Cinatrin C3), 1.68 (1H, m, H-6 CinatrinCl), 1.50 (1H, m, H-7 
CinatrinCl), 1.46 (2H, m, H-7 Cinatrin C3), 1.36 (1H, m, H-7 
Cinatrin Cl), 1.29 (18H, Shroud, 4CH2i Cinatrin C3, 
Cinatrin Cl), 0.88 (3H, m, ‘CH3 Cinatrin C3, Cinatrin C1). 
[0181] l3C-NMR (75 MHZ, CD3OD). Cinatrin C3: 6 176.8, 
172.6, 170.3, 82.1, 81.2, 80.8, 33.2, 32.1, 31.4, 30.8, 30.7, 
30.5, 30.4, 23.6, 22.6, 14.5; Cinatrin Cl: 6 175.8, 172.0, 88.6, 
85.7, 74.8, 33.4, 32.3, 31.6, 30.5, 30.4, 30.3, 30.1, 23.8, 22.4, 
14.3. 
[0182] LRMS (EI): m/Z 374 (M", 0), 355 (1), 331 (1), 297 
(3), 267 (3), 249 (3), 207 (5), 197 (93), 57(100). 
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1. A process for obtaining a compound of formula (ll) 
(11) 
0 
OH 
0 
R2 
CO2R3 
R5020 OH 
wherein 
R2 is a Clo-Cl5 alkyl group; and 
R3 and R5 are independently selected from a substituted or 
unsubstituted C l-C2O alkyl group; 
its stereoisomers, or mixtures thereof; 
Which process comprises dihydroxylating the double bond of 
a compound of formula (III) 
(III) 
0 0R5 
0 
R30 / 
R10 
R2 
OH 
0 
Wherein 
R2, R3 and R5 have the previously mentioned meaning; and 
R1 is selected from a substituted or unsubstituted Cl-C2O 
alkyl group. 
2. The process according to claim 1, Wherein the compound 
of formula (III) is a compound of formula (Illa), or its enan 
tiomers 
(Illa) 
Wherein R1, R2, R3 and R5 are as de?ned in claim 1; 
and the compound of formula (11) obtained is a compound of 
formula (Ila), or its enantiomers 
(Ila) 
....|||CO2R3 
R5020 OH 
Wherein R2, R3 and R5 are as de?ned in claim 1. 
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3. The process according to claim 1, Wherein the dihy 
droxylation is performed in the presence of osmium tetrox 
ide/N-methylmorpholine-N-oxide or potassium permangan 
ate. 
4. (canceled) 
5. A process according to claim 1, Wherein the synthesis of 
a compound of formula (III) 
(III) 
0 0R5 
0 
R30 / 
R10 
R2 
OH 
0 
Wherein 
R1, R3 and R5 are independently selected from a substituted 
or unsubstituted C l-C2O alkyl group; and 
R2 is a Clo-Cl5 alkyl group; 
its stereoisomers, or mixtures thereof; 
Which comprises 
(a) reacting a compound of formula (V) 
(V) 
R30 
R10 
R2 
OH 
Wherein 
R1, R2 and R3 are as de?ned above; 
in the presence of a compound of formula C(11) 
(x11) 
0 
PPh3 RSOb 
Wherein 
R5 is as de?ned above; 
Or 
(b) oxidizing With a peroxide or With sodium periodate a 
compound of formula (V 1) 
(VI) 
R30 0 
o 
RGSe 0R5 
R10 
R2 
0 
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wherein 
R1, R2, R3 and R5 are as de?ned above; and 
R6 is selected from the group formed by Cl-C3 alkyl and 
phenyl. 
6. The process according to claim 5, Wherein the compound 
of formula (V1) is prepared by 
(i) reacting in the presence of a base a compound of formula 
(V11) 
(V11) 
O 
O 
R30 
R10 
R2 
O 
Wherein 
R1, R2 and R3 are de?ned as in claim 5; 
With a compound of formula @(V) 
RGSeX (XV) 
Wherein 
R6 is de?ned as in claim 5; and 
X is a halogen selected from C1 and Br; 
to obtain a compound of formula (X111) 
(X111) 
O 
O 
R30 
R10 
R2 
SeR6 
O 
Wherein 
R1, R2, R3 and R6 are de?ned as in claim 5; and 
(ii) reacting said compound of formula (XIII) in the presence 
of a base With a phosphonate of formula (XIV) 
(XIV) 
o 
Wherein 
R5 is de?ned as in claim 5; and 
R7 is a Cl-C3 alkyl group. 
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7. The process according to claim 5, Wherein the compound 
of formula (V) is prepared by 
(i) reacting a compound of formula (V11) 
(V11) 
O 
O 
R30 
R10 
R2 
O 
Wherein 
R1, R2 and R3 are de?ned as in claim 5; 
With a trialkylsilyl halide or With a trialkylsilyl tri?ate in the 
presence of a base to obtain a compound of formula Ci) 
0 (X) 
0R4 
R30 
R10 
R2 
0 
Wherein 
R1, R2 and R3 are de?ned as in claim 5; and 
R4 is a trialkylsilyl group; 
(ii) reacting said compound of formula (X) With an epoxidiZ 
ing agent to obtain a compound of formula 0(1) 
0 (X1) 
0R4 
R30 
0 
R10 
R2 
0 
Wherein 
R1, R2 and R3 are de?ned as in claim 5; and 
R4 is as de?ned above; and 
(iii) reacting said compound of formula Gil) With a com 
pound capable of generating ?uoride ions. 
8. The process according to claim 7, Wherein said epoxi 
diZing agent is selected from the group consisting of 3 chlo 
roperoXybenZoic acid, 2-sulfonyloxaZiridines and the HOP. 
CH3CN complex. 
9. The process according to claim 7, Wherein the epoxida 
tion is asymmetric. 
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10. The process according to claim 6, wherein the com 
pound of formula (V H) is prepared by reacting in the presence 
of a base a compound of formula (V111) 
(V111) 
R10 
Y R2 
0 
wherein 
R1 and R2 are de?ned as in claim 6; 
With an oxalic acid diester of formula (IX) 
(IX) 
0 0R3 
0 0R3 
Wherein 
R3 is de?ned as in claim 6. 
11-17. (canceled) 
18. A process for preparing compounds of formula (la) 
and/ or (lb) 
la 
0 
OH 
0 
R2 
COZH 
H020 OH 
lb 
0 
HO 
O 
HO R2 
H020 COZH 
Wherein 
R2 is a Clo-Cl5 alkyl group; 
their stereoisomers, or mixtures thereof, or mixtures of the 
compounds of formula (la) and (lb) or mixtures of their 
stereoisomers, 
Which comprises 
(i) dihydroxylating the double bond of a compound of for 
mula (III) 
(III) 
0 0R5 
0 
R30 / 
R10 
R2 
OH 
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wherein 
R1 is selected from a substituted or unsubstituted Cl-C2O 
alkyl group; 
R2 is as de?ned above; and 
R3 and R5 are independently selected from a substituted or 
unsubstituted C l-C2O alkyl group; 
to obtain a compound of formula (ll) 
(11) 
0 
OH 
0 
R2 
CO2R3 
R5020 OH 
Wherein 
R2, R3 and R5 are as de?ned above; 
its stereoisomers, or mixtures thereof; 
(ii) hydrolyZing said compound of formula (II) in the pres 
ence of an alkali or alkaline earth metal hydroxide, or of an 
alkali or alkaline earth metal carbonate; and 
(iii) acidifying the reaction medium; 
Wherein the R3 and R5 groups are labile under the basic 
conditions of step (ii). 
19. The process according to claim 18, for preparing com 
pounds of formula (la') and (lb'), or their enantiomers 
Wherein 
R2 is as de?ned in claim 18; 
the compound of formula (III) is a compound of formula 
(Illa), or its enantiomers 
(Illa) 
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wherein R1, R2, R3 and R5 are as de?ned in claim 18; and 
the compound of formula (II) is a compound of formula (Ila), 
or its enantiomers 
(Ila) 
Wherein R2, R3 and R5 are as de?ned in the claim 18. 
20. A process for preparing a compound of formula (la) 
la 
0 
OH 
0 
R2 
COZH 
HOZC OH 
Wherein 
R2 is a Clo-Cl5 alkyl group; 
its stereoisomers, or mixtures thereof, 
Which comprises 
(i) dihydroxylating the double bond of a compound of for 
mula (III) 
(III) 
0 0R5 
0 
R30 / 
R10 
R2 
OH 
0 
wherein 
R1 is selected from a substituted or unsubstituted Cl-C2O 
alkyl group; 
R2 is as de?ned above; and 
R3 and R5 are independently selected from a substituted or 
unsubstituted C l-C2O alkyl group; 
to obtain a compound of formula (ll) 
(11) 
0 
on 
0 
R2 
CO2R3 
R5020 OH 
Wherein 
R2, R3 and R5 are as de?ned above; 
its stereoisomers, or mixtures thereof; and 
(ii) transforming under non-basic conditions the carboxy 
ester groups of the lactone ring of the compound of formula 
(II) to obtain the corresponding carboxy acid groups. 
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21. (canceled) 
22. (canceled) 
23. (canceled) 
24. A compound selected from the group consisting of: 
(a) formula (ll) 
(11) 
0 
on 
0 
R2 
CO2R30; 
R5020 OH 
its stereoisomers, or mixtures thereof, as de?ned in claim 1; 
(b) formula (III) 
(III) 
0 0R5; 
0 
R30 / 
R10 
R2 
on 
0 
its stereoisomers, or mixtures thereof, as de?ned in claim 1; 
(c) formula (V) 
(V) 
R30 
R10 
R2. 
O 
E 
O 
its stereoisomers, or mixtures thereof, as de?ned in claim 5; 
(d) formula (V 1) 
(VI) 
R30 0 
o 
RGSe 0R5; 
R10 
R2 
0 
its stereoisomers, or mixtures thereof, as de?ned in claim 5; 
(e) formula (V 11) 
(V11) 
R30 
R10 
R2. cite O 
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its stereoisomers, or mixtures thereof, as de?ned in claim 6; 
(f) formula Q() 
(X) 
0 
OR“; 
R30 
R10 
R2 
its stereoisomers, or mixtures thereof, as de?ned in claim 7; 
(g) formula Gil) 
(XI) 
0 
OR“; 
R30 
0 
R10 
R2 
0 
and 
its stereoisomers, or mixtures thereof, as de?ned in claim 7; 
(h) formula @111) 
(X111) 
0 
0, 
R30 
R10 
R2 
SeR6 
0 
its stereoisomers, or mixtures thereof, as de?ned in claim 6; 
Wherein 
R1, R3 and R5 are independently selected from a substituted 
or unsubstituted C l-C2O alkyl group; 
R2 is selected from a Clo-Cl5 alkyl group; 
R4 is a trialkylsilyl group; and 
R6 is selected from the group formed by Cl-C3 alkyl and 
phenyl; 
its stereoisomers, or mixtures thereof, 
With the proviso that the compound of formula (II) is not 
25. The compound according to claim 24, selected from the 
group consisting of Formula (V), Formula (VI), Formula 
(VII), Formula (X), Formula (XI), and Formula Qilll), 
Wherein Rl:R3:Me and R2:n-dodecyl. 
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26. The process according to claim 7, Wherein the com 
pound of formula (V H) is prepared by reacting in the presence 
of a base a compound of formula (V 111) 
R10 
Y R2 
0 
(VIII) 
wherein 
R1 and R2 are de?ned as in claim 7; 
With an oxalic acid diester of formula (IX) 
3 (IX) 
0 OR 
0 0R3 
Wherein 
R3 is de?ned as in claim 7. 
27. A process according to claim 1, Which further com 
prises the step of hydrolyZing said compound of formula (II) 
in the presence of an alkali or alkaline earth metal hydroxide, 
or of an alkali or alkaline earth metal carbonate; and of acidi 
fying the reaction medium; 
Wherein the R3 and R5 groups are labile under the basic 
conditions of step of said hydrolyZation; 
to obtain compounds of formula (la) and/or (lb) 
la 
0 
OH 
0 
R2 
COZH 
H020 OH lb 
0 
HO 
0 
HO R2 
H020 cozn 
Wherein 
R2 is a Clo-Cl5 alkyl group; 
their stereoisomers, or mixtures thereof, or mixtures of the 
compounds of formula (la) and (lb) or mixtures of their 
stereoisomers. 
28. A process according to claim 1, Which further com 
prises the step of transforming under non-basic conditions the 
carboxy ester groups of the lactone ring of the compound of 
formula (11) into the corresponding carboxy acid groups to 
obtain a compound of formula (la) 
la 
0 
OH 
0 
R2 
COZH 
HOZC OH 
Wherein 
2 ~ . R is a Clo-Cl5 alkyl group, 
its stereoisomers, or mixtures thereof. 
* * * * * 
